GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Sophia Genetics SA (NAS:SOPH) » Definitions » ROCE %

Sophia Genetics (Sophia Genetics) ROCE % : -46.80% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Sophia Genetics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sophia Genetics's annualized ROCE % for the quarter that ended in Mar. 2024 was -46.80%.


Sophia Genetics ROCE % Historical Data

The historical data trend for Sophia Genetics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sophia Genetics ROCE % Chart

Sophia Genetics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROCE %
Get a 7-Day Free Trial -66.90 -56.51 -36.23 -34.19 -40.20

Sophia Genetics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.76 -40.67 -35.90 -50.71 -46.80

Sophia Genetics ROCE % Calculation

Sophia Genetics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-77.907/( ( (243.838 - 26.81) + (206.156 - 35.621) )/ 2 )
=-77.907/( (217.028+170.535)/ 2 )
=-77.907/193.7815
=-40.20 %

Sophia Genetics's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-75.024/( ( (206.156 - 35.621) + (180.258 - 30.193) )/ 2 )
=-75.024/( ( 170.535 + 150.065 )/ 2 )
=-75.024/160.3
=-46.80 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sophia Genetics  (NAS:SOPH) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Sophia Genetics ROCE % Related Terms

Thank you for viewing the detailed overview of Sophia Genetics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sophia Genetics (Sophia Genetics) Business Description

Traded in Other Exchanges
Address
Rue du Centre 172, Saint-Sulpice, CHE, CH-1025
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities.